Business Context and Reporting Period
Company: ADVENTRX Pharmaceuticals, Inc. (Note: Request metadata listed "Savara Inc," but the filing text identifies the registrant as ADVENTRX Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: ADVENTRX is a development-stage specialty pharmaceutical company focused on in-licensing, developing, and commercializing proprietary product candidates for cancer treatment. The company has not yet marketed or sold any products. Its lead candidates are ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion). The company suspended most operations in March 2009 to conserve cash but restarted activities following equity financings in June 2009.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Balance Sheet (Sep 30, 2009) |
|---|---|---|---|
| Total Revenues | $0 | $300,000 | N/A |
| Net Loss (Applicable to Common Stock) | $(2,728,675) | $(9,713,642) | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.10) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $3,159,610 |
| Working Capital | N/A | N/A | $1,562,467 |
| Total Assets | N/A | N/A | $3,830,305 |
| Total Liabilities | N/A | N/A | $2,205,522 |
| Accumulated Deficit | N/A | N/A | $(135,560,100) |
Cash Flow (Nine Months Ended Sep 30, 2009):
- Net cash used in operating activities: $(9,986,154)
- Net cash provided by investing activities: $16,000
- Net cash provided by financing activities: $3,279,860
Material Changes vs. Prior Period
- Revenue: No revenue was recognized in the three months ended September 30, 2009, compared to $500,000 in the same period in 2008. For the nine months, revenue was $300,000 (from a license fee) compared to $500,000 in 2008.
- Operating Expenses: Total operating expenses decreased significantly due to workforce reductions and suspended activities.
- R&D Expenses: Decreased 70% to $1.4 million for the quarter (from $4.7 million) and 65% to $4.5 million for the nine months (from $13.1 million).
- SG&A Expenses: Decreased 57% to $0.9 million for the quarter (from $2.1 million) and 47% to $3.7 million for the nine months (from $7.1 million).
- Liquidity: Cash and cash equivalents decreased from $9.8 million at December 31, 2008, to $3.2 million at September 30, 2009, reflecting operating losses and reduced cash reserves.
- Equity: The company completed multiple registered direct equity financings in June, July, August, and October 2009, issuing Series A, B, C, and D Convertible Preferred Stock. All Series A, B, and C shares issued during the period were converted to common stock.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing states there is substantial doubt about the company's ability to continue as a going concern beyond 2010. Management anticipates that current cash plus proceeds from an October 9, 2009 financing ($5.1 million net) will sustain operations through 2010. Additional capital is required to commercialize ANX-530 or continue developing ANX-514.
- Unusual Items:
- Deemed Dividends: Net loss included non-cash deemed dividend expenses of approximately $0.4 million for the quarter and $1.6 million for the nine months related to beneficial conversion features in recent equity financings.
- Severance: The company recorded severance charges of $174,000 (Jan 2009) and $160,000 (Apr 2009) due to workforce reductions.
- Risks:
- Inability to raise additional capital on a timely basis.
- Regulatory risks regarding FDA approval of ANX-530 and ANX-514.
- Delisting risk from NYSE Amex due to low stock price or equity levels.
- Reliance on a significantly reduced workforce (only two full-time employees as of the report date).
- Outlook: The company is focused on raising capital to submit a New Drug Application (NDA) for ANX-530 and evaluating strategic options, including partnerships or mergers.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.2 million cash balance plus the $5.1 million October 2009 financing to cover operations through 2010, given the high burn rate of drug development.
- Financing Terms: Review the terms of the Series D Convertible Preferred Stock and associated warrants (exercise price $0.1468) issued in October 2009, including beneficial ownership limitations.
- Regulatory Status: Confirm the current status of the ANX-530 bioequivalence study and the timeline for NDA submission, as this is critical for future revenue.
- Going Concern: Assess the likelihood of securing additional funding beyond 2010, as the company explicitly states it may need to seek bankruptcy protection or liquidate if capital is not raised.
- Internal Controls: Note the significant turnover in financial personnel and the appointment of a non-financial officer as Principal Financial Officer; verify the effectiveness of internal controls over financial reporting.